{"schema_version":"secwatch.filing_event.v1","accession":"0001651944-23-000065","form_type":"8-K","ticker":null,"cik":"0001651944","company_name":"DermTech, Inc.","filed_at":"2023-06-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.849830+00:00","generated_at":"2026-06-13T15:33:32.166410+00:00","sec_items":["2.05","5.02","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"DermTech: 15% workforce cut, pipeline suspended, cash runway to Q1 2025","bullets":["Reduction of ~40 employees (~15%), completion expected by end-of-July 2023.","Annualized cost savings of $25M-$30M; one-time charge ~$2M in Q2 2023.","All pipeline programs suspended; focus solely on DermTech Melanoma Test revenue.","Cash runway extended into Q1 2025; $108.4M cash as of March 31, 2023.","Chief Commercial Officer Todd Wood to depart July 3, 2023; separation terms pending."],"urls":{"canonical":"https://secwatch.observer/filing/0001651944-23-000065","json":"https://secwatch.observer/filing/0001651944-23-000065.json","markdown":"https://secwatch.observer/filing/0001651944-23-000065.md","text":"https://secwatch.observer/filing/0001651944-23-000065.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1651944/000165194423000065/0001651944-23-000065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1651944/000165194423000065/dmtk-20230626.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T15:33:32.166410+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"69593f4fe8","claim":"Todd Wood departed as chief commercial officer at DermTech, Inc..","evidence_excerpt":"On June 26, 2023, it was determined that Todd Wood’s last day of employment as chief commercial officer of the Company will be July 3, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1651944/000165194423000065/0001651944-23-000065-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"depart"},{"label":"Role","value":"chief commercial officer"}],"fact_type":"executive_change"},{"claim_id":"c146d62c537355e678b94a8b7766b3e832cd2c2f","claim":"DermTech, Inc. announced a restructuring with charges of approximately $2 million affecting sales, marketing and G&A functions (approximately 40 employees, or approximately 15%).","evidence_excerpt":"approximately 40 employees, or approximately 15%, and will extend the Company’s cash runway. The Company estimates that it will incur aggregate pre-tax charges of approximately $2 million in connection with the Reduction in Force, primarily consisting of severance payments, employee benefits, outplacement services and related costs. The Company expects that the","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1651944/000165194423000065/0001651944-23-000065-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $2 million"},{"label":"Affected area","value":"sales, marketing and G&A functions"},{"label":"Headcount","value":"approximately 40 employees, or approximately 15%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}